Mike Tyson has attributed his incredible body transformation to stem cell therapy and a rigid vegan diet.
Mike Tyson has attributed his incredible body transformation to stem cell therapy and a rigid vegan diet.
SAN DIEGO, May 28, 2020 /PRNewswire/ --Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader (KOL) call discussing the treatment of Epstein-Barr virus (EBV)-associated lymphoma on Friday, June 5th at 12 P.M.
The global regenerative medicine market is anticipated to gain the market worth of US$ 178.62 billion by 2026, expanding at a CAGR of 31.5% during the forecast period 2020-2026.The major reasons that escalate the adoption of regenerative medicine arethe growing prevalence of genetic disorders and chronic diseasesand technological advancements in the regenerative medicine field.Increasing acceptance of regenerative medicine for organ transplants paired with increasing pipeline activity is considered as one of the major opportunity areas for market players. The emergence of stem cell technology, untapped potential of nanotechnology, increasing prevalence of chronic diseases & trauma emergencies, advancement in monitoring devices and surgical technologies, rise in incidence of degenerative diseases, and shortage of organs for transplantation and increase in focus on stem cells and growth in R&D activities in emerging economies are expected to supplement the market growth.
The global regenerative medicine market is estimated to grow on the back of rising healthcare expenditure with increasing demand for efficient disease treating practices coupled with growing technological developments and discoveries.
Global Precision Medicine market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin. The company profiles of all the key players and brands that are dominating the Precision Medicine market with moves like product launches, joint ventures, merges and accusations which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report
The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain.
The Human Embryonic Stem Cells (HESC) Market is analyzed in depth in the report, with the main aim of providing precise market data and useful recommendations so that players can achieve strong growth in the future. The report is compiled by experienced experts and market analysts, which makes it very authentic and reliable.
In 2029, the Human Embryonic Stem Cells (HESC) market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Human Embryonic Stem Cells (HESC) market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Human Embryonic Stem Cells (HESC) market size is projected to inflate with a CAGR of xx% during the forecast period.
We know that the bodys immune system is important for keeping everything in check and protecting us. But a lot of us dont realise that the brain also has an immune system.
SALT LAKE CITY, Utah, May 29, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data from the first clinical studies evaluating the oral investigational agents TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, and TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors. These results were presented in poster presentations at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, being held May 29-31, 2020.
Recent Comments